Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial

医学 人口 内科学 临床终点 安慰剂 临床试验 物理疗法 病理 替代医学 环境卫生
作者
Gıancarlo Comı,Ludwig Kappos,Krzysztof Selmaj,Amit Bar‐Or,Douglas L. Arnold,Lawrence Steinman,Hans‐Peter Hartung,Xavier Montalbán,Eva Havrdová,Bruce Cree,James K. Sheffield,Neil Minton,Kartik Raghupathi,Ning Ding,Jeffrey A. Cohen
出处
期刊:Lancet Neurology [Elsevier BV]
卷期号:18 (11): 1009-1020 被引量:236
标识
DOI:10.1016/s1474-4422(19)30239-x
摘要

Ozanimod, a sphingosine 1-phosphate receptor modulator, selectively binds to receptor subtypes 1 and 5 with high affinity. The RADIANCE phase 2 study showed that ozanimod had better efficacy than placebo on MRI measures, with a favourable safety profile, in participants with relapsing multiple sclerosis. The SUNBEAM study aimed to assess the safety and efficacy of ozanimod versus intramuscular interferon beta-1a in participants with relapsing multiple sclerosis.SUNBEAM was a randomised, double-blind, double-dummy, active-controlled phase 3 trial done at 152 academic medical centres and clinical practices in 20 countries. We enrolled participants aged 18-55 years with relapsing multiple sclerosis, baseline expanded disability status scale (EDSS) score of 0·0-5·0, and either at least one relapse within the 12 months before screening or at least one relapse within 24 months plus at least one gadolinium-enhancing lesion within 12 months before screening. Participants were randomly assigned 1:1:1 by a blocked algorithm stratified by country and baseline EDSS score to at least 12 months treatment of either once-daily oral ozanimod 1·0 mg or 0·5 mg or weekly intramuscular interferon beta-1a 30 μg. Participants, investigators, and study staff were masked to treatment assignment. The primary endpoint was annualised relapse rate (ARR) during the treatment period and was assessed in the intention-to-treat population. Safety was assessed in all participants according to the highest dose of ozanimod received. This trial is registered at ClinicalTrials.gov, number NCT02294058 and EudraCT, number 2014-002320-27.Between Dec 18, 2014, and Nov 12, 2015, 1346 participants were enrolled and randomly assigned to ozanimod 1·0 mg (n=447), ozanimod 0·5 mg (n=451), or interferon beta-1a (n=448). 91 (6·8%) participants discontinued the study drug (29 in the ozanimod 1·0 mg group; 26 in the ozanimod 0·5 mg group; and 36 in the interferon beta-1a group). Adjusted ARRs were 0·35 (0·28-0·44) for interferon beta-1a, 0·18 (95% CI 0·14-0·24) for ozanimod 1·0 mg (rate ratio [RR] of 0·52 [0·41-0·66] vs interferon beta-1a; p<0·0001), and 0·24 (0·19-0·31) for ozanimod 0·5 mg (RR 0·69 [0·55-0·86] vs interferon beta-1a; p=0·0013). Few ozanimod-treated participants discontinued treatment because of adverse events (13 [2·9%] who received ozanimod 1·0 mg; seven [1·5%] who received ozanimod 0·5 mg; and 16 [3·6%] who received interferon beta-1a). No first-dose, clinically significant bradycardia or second-degree or third-degree atrioventricular block was reported. The incidence of serious adverse events was low and similar across treatment groups (13 [2·9%] participants who received ozanimod 1·0 mg; 16 [3·5%] who received ozanimod 0·5 mg; and 11 [2·5%] who received interferon beta-1a). No serious opportunistic infections occurred in ozanimod-treated participants.In participants with relapsing multiple sclerosis treated for at least 12 months, ozanimod was well tolerated and demonstrated a significantly lower relapse rate than interferon beta-1a. These findings provide support for ozanimod as an oral therapy for individuals with relapsing multiple sclerosis.Celgene International II.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
sheila完成签到,获得积分10
1秒前
1秒前
枫叶的虫子完成签到,获得积分10
2秒前
2秒前
Pooh发布了新的文献求助10
3秒前
3秒前
4秒前
深情安青应助莫非采纳,获得10
5秒前
向阳而生o完成签到,获得积分10
5秒前
xxx发布了新的文献求助10
5秒前
6秒前
llll发布了新的文献求助10
7秒前
yao发布了新的文献求助30
7秒前
8秒前
loski发布了新的文献求助10
8秒前
可爱的函函应助偷乐采纳,获得10
10秒前
清晾油完成签到,获得积分10
10秒前
11秒前
脑洞疼应助科研通管家采纳,获得10
11秒前
科目三应助科研通管家采纳,获得10
11秒前
坦率的匪应助科研通管家采纳,获得10
11秒前
科研通AI5应助科研通管家采纳,获得10
11秒前
JamesPei应助科研通管家采纳,获得10
11秒前
解语花应助科研通管家采纳,获得50
11秒前
czh应助科研通管家采纳,获得10
11秒前
JamesPei应助科研通管家采纳,获得10
11秒前
科研通AI2S应助科研通管家采纳,获得10
11秒前
bkagyin应助科研通管家采纳,获得10
11秒前
Hello应助科研通管家采纳,获得10
11秒前
坦率的匪应助科研通管家采纳,获得10
11秒前
ludov应助科研通管家采纳,获得10
11秒前
12秒前
搜集达人应助科研通管家采纳,获得10
12秒前
隐形曼青应助科研通管家采纳,获得10
12秒前
坦率的匪应助科研通管家采纳,获得10
12秒前
11完成签到,获得积分20
12秒前
精明谷完成签到,获得积分10
12秒前
13秒前
13秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
‘Unruly’ Children: Historical Fieldnotes and Learning Morality in a Taiwan Village (New Departures in Anthropology) 400
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3988838
求助须知:如何正确求助?哪些是违规求助? 3531250
关于积分的说明 11252914
捐赠科研通 3269838
什么是DOI,文献DOI怎么找? 1804820
邀请新用户注册赠送积分活动 881943
科研通“疑难数据库(出版商)”最低求助积分说明 809028